Comment from The FCS Foundation

Summary: The FCS Foundation, a patient-led nonprofit for Familial Chylomicronemia Syndrome (FCS), supports the Haystack Project's proposed framework for improving drug approval for rare diseases. They argue that the FDA should adopt modern statistical methods (like Bayesian adaptive designs) and patient-specific endpoints to address the unique challenges of small patient populations.